



August 20, 2015

## **ImmunoGen, Inc. Announces Webcast of its Analyst and Investor Event on September 18, 2015**

WALTHAM, Mass.--(BUSINESS WIRE)-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that investors, journalists and the general public are invited to listen to a live webcast of the Company's analyst and investor community meeting on September 18, 2015.

The event will focus on ImmunoGen's strong foundation for growth, including the advancement of its multi-product pipeline, its proprietary technology that is enabling the development of novel anticancer therapies and the Company's core competencies that position it for success.

The video webcast will begin at 8:30 a.m. ET and will be accessible through the Investors section of the Company's website, [www.immunogen.com](http://www.immunogen.com). The meeting is expected to last approximately three hours, including a short break. An archive of the webcast will be available on the Company's website through October 2, 2015.

### **About ImmunoGen, Inc.**

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The Company utilizes its ADC technology with its antibodies to create ImmunoGen product candidates and also out-licenses limited rights to use its technology to other companies. Roche's Kadcyla<sup>®</sup> is the first marketed product with ImmunoGen's ADC technology. More information about the Company can be found at [www.immunogen.com](http://www.immunogen.com).

Kadcyla<sup>®</sup> is a registered trademark of Genentech, a member of the Roche Group.

View source version on [businesswire.com](http://www.businesswire.com/news/home/20150820006194/en/): <http://www.businesswire.com/news/home/20150820006194/en/>

For Investors:  
ImmunoGen, Inc.  
Carol Hausner, 781-895-0600  
[info@immunogen.com](mailto:info@immunogen.com)

or  
For Media:  
Pure Communications, Inc.  
Dan Budwick, 973-271-6085

Source: ImmunoGen, Inc.

News Provided by Acquire Media